Severe orthostatic hypotension after left atrial appendage occlusion Authors: Christopher Kopreski, Edward H Puckett, Antonio Sotolongo-Fernandez, Kent R Nilsson Published: 2026 Key Teaching Points •Orthostatic hypotension is a rare complication of left atrial appendage occlusion (LAAO) that can occur despite proper device placement. Symptoms may present within hours of the procedure, highlighting the need for careful postoperative monitoring. Orthostatic hypotension is a rare complication of left atrial appendage occlusion (LAAO) that can occur despite proper device placement. Symptoms may present within hours of the procedure, highlighting the need for careful postoperative monitoring. •The etiology of post-LAAO orthostatic hypotension may be related to atrial natriuretic peptide secretion and clinically significant diuresis. Medications with hypotensive side effects and certain preexisting conditions may predispose patients to this complication. The etiology of post-LAAO orthostatic hypotension may be related to atrial natriuretic peptide secretion and clinically significant diuresis. Medications with hypotensive side effects and certain preexisting conditions may predispose patients to this complication. •Pharmacologic treatment of orthostatic hypotension, intravenous volume expansion, adjustment of home medications, and supportive care over time may resolve hypotensive symptoms without the need for device removal. Pharmacologic treatment of orthostatic hypotension, intravenous volume expansion, adjustment of home medications, and supportive care over time may resolve hypotensive symptoms without the need for device removal. Introduction Atrial fibrillation (AF) is a common cardiac arrhythmia with increasing prevalence.1,2 AF is associated with significant morbidity and is responsible for roughly a quarter of ischemic strokes.3, 4, 5 The primary origin of thromboemboli in patients with AF is the left atrial appendage (LAA).1 LAA occlusion (LAAO) has emerged as an effective and safe method for reducing the risk of ischemic stroke and mortality in patients with AF, which can be performed via endocardial occlusion or epicardial closure.4,6 Epicardial approaches have been associated with modest reductions in blood pressure and serum sodium, along with changes in catecholamines, aldosterone, and atrial natriuretic peptide (ANP). However, these trends have not been consistently observed with endocardial approaches.7, 8, 9, 10 Severe orthostatic hypotension (OH) after LAAO is exceptionally rare regardless of approach; only 1 previous case has been reported, which occurred after implantation of the Amplatzer™ cardiac plug (ACP) and resolved only with device removal.11 To date, OH has not been recognized as a complication of the Amplatzer Amulet™, a second-generation device designed to improve upon the ACP. We report the first case of severe OH after implantation of the Amplatzer Amulet. This is also the first report of severe post-LAAO OH successfully managed with pharmacologic therapy rather than device removal. Case report This case describes a 70-year-old male with a history of paroxysmal AF who was contraindicated for oral anticoagulation owing to a fall history and gait instability. Medical history included hypertension, benign prostatic hyperplasia, gastroesophageal reflux disease with esophagitis, type 2 diabetes mellitus with peripheral neuropathy, hyperlipidemia, uncomplicated presenile dementia, and previous deep venous thrombosis. There was no recorded history of OH. His CHA2DS2-VASc and HAS-BLED scores were 5 and 4, respectively. The benefits and risks of oral anticoagulation compared with LAAO were discussed, and through shared decision making the patient consented to undergo LAAO with the Amplatzer Amulet to reduce the risk of cerebrovascular accident. The patient entered the electrophysiology laboratory in a fasted, nonsedated state and was placed under general anesthesia. Preprocedural transesophageal echocardiography demonstrated normal right and left ventricular performance, intact interatrial septum, and no aortic atherosclerosis. The LAA was clearly visualized with a maximal orifice 16-17 mm in diameter, a pectinated chicken-wing morphology, and no evidence of mass or thrombus (Figure 1C). A: Intraprocedural fluoroscopy showing good compression of Amulet in LAA. B: Intraprocedural fluoroscopy with contrast injection showing no leakage into LAA. C: Preimplant TEE showing diameter of LAA and no thrombus or mass. D: Postimplant TEE showing no residual LAA color flow on Doppler. LAA = left atrial appendage; TEE = transesophageal echocardiography. The procedure was completed percutaneously using a femoral approach. Transseptal catheterization was performed without complication, using intracardiac echocardiography and fluoroscopy for guidance. LAA pressure measured 16 mm Hg and contrast angiography visualized the LAA before implant. An 18 mm Amplatzer Amulet was advanced into the LAA and deployed. Fluoroscopy showed subsequent occlusion of the LAA, excellent compression of the device, and no visible device protrusion into the left atrium. A “tug test” confirmed that the device was adequately seated (Figure 1A). Contrast injection showed no leaks into the LAA (Figure 1B), and the device was released. Postimplant transesophageal echocardiography showed preserved left ventricular systolic performance, no postprocedural pericardial effusion, and no residual LAA color flow (Figure 1D). The total fluoroscopy time was 14.8 minutes (466 mGy) with 30 mL of contrast administered. Catheters were removed and hemostasis was achieved using manual pressure and 2 vascular closure systems, including VASCADE® and Perclose ProGlide™. 4 hours after the operation, the patient developed severe OH upon ambulation after bed rest, with blood pressures as low as 63/43 mm Hg (Figure 2). A repeat echocardiogram and chest computed tomography (CT) scan were performed to rule out any possible mechanical injury leading to hypotension. Once this was excluded, the patient was admitted and midodrine was initiated. Hematocrit was 39.7% and hemoglobin 13.5 g/dL. From the end of the procedure to postoperative day 1, the patient had a cumulative urine output of 3.8 L with a 0.33-L intake, resulting in an acute negative fluid balance of 3.47 L (Figure 3). Serum sodium also decreased by 3 mmol/L, from a preprocedural value of 141 to 138 mmol/L on postoperative day 1. High variability of BPs during admission. Arrows indicate transitions to upright positions. Representative orthostatic BPs shown per day. BP = blood pressure. Daily intake and output during hospital admission. Despite aggressive administration of isotonic intravenous fluids, OH persisted through postoperative day 3, leading to escalation of midodrine and initiation of fludrocortisone. Among the patient’s home medications, finasteride, metoprolol succinate, donepezil, and memantine were withheld and trazodone dosage decreased. During this time, the patient had an episode of paroxysmal AF with rapid ventricular response, for which amiodarone and digoxin were initiated. A limited 2-dimensional echocardiogram was performed and was unremarkable. No signs of infection were found on the chest radiograph. On postoperative day 4, serum sodium increased to 140 mmol/L and OH started to improve, although symptoms persisted. Fludrocortisone dosage was increased, and fluid administration continued. A cardiac-gated CT scan was obtained to evaluate the position of the Amulet and showed a normally seated device. On postoperative day 6, the patient had only mild, asymptomatic OH. After demonstrating safe ambulation, the patient was discharged with instructions to (1) continue midodrine, fludrocortisone, and amiodarone; (2) continue withholding previously specified home medications; and (3) maintain anticoagulation with clopidogrel for 6 months in conjunction with daily aspirin. Cumulative fluid intake and output over the hospital stay were 13.09 and 16.95 L, respectively (Figure 3). Throughout the 2-month follow-up period, the patient’s blood pressures remained stable without any syncope or dizziness (Figure 4). Postdischarge blood pressures remain stable during a 2-month follow-up. Discussion The Amplatzer Amulet is the second-generation LAAO device developed by Abbott Laboratories that improves upon its predecessor, the ACP. Both devices are made of nitinol mesh and comprise a distal lobe that fits within the LAA and a proximal disc that covers the ostium; however, the Amplatzer Amulet has more stabilizing hooks, has a larger lobe and disc, and is preloaded for safer and more efficient delivery.12 Comparative studies have shown reduced fluoroscopy times, peridevice leaks, and resizing rate in those with the Amplatzer Amulet compared with the ACP, but both have similar clinical outcomes.12,13 Known complications of the Amplatzer Amulet include pericardial effusion, device embolization, and cardiac tamponade.14 Blood pressure reduction is commonly observed in patients undergoing epicardial LAA closure. In 1 prospective observational study9, more than 75% of patients experienced blood pressure decline within 48 hours, which was successfully managed with adjustment of antihypertensive medications. In contrast to our patient, these reductions in systolic blood pressure are typically modest (<20 mm Hg) and may persist for up to 1 year after LAA closure.7,9 Lakkireddy et al7 reported a different pattern in patients implanted with an earlier endocardial device (Watchman, Boston Scientific), in which systolic blood pressure decreased by an average of 18 mm Hg immediately after the procedure but not at 24 hours or beyond.7 Immediate intra- and postprocedural OH may result from mechanostimulation of ganglionated plexi within the left atrium, which can cause a vagal response in both human and animal models.15,16 In contrast to the transient, modest hypotension observed in Lakkireddy et al,7 Cruz-Gonzalez et al11 described a novel case of a 72-year-old woman who developed severe, recurrent syncopal episodes >48 hours after ACP implantation. In this case, the device partially covered the posterior leaflet of the mitral valve, and symptoms resolved only after surgical removal. The authors proposed that the device’s position could have caused “dynamic” valvular obstruction and hemodynamic compromise, similar to those with atrial myxomas.17 Given the larger dimensions of the Amplatzer Amulet, pulmonary artery (PA) injury or stenosis should also be considered in patients with postprocedural hemodynamic compromise. PA injury is a rare complication of endocardial LAAO devices, typically presenting within 24 hours of the procedure with pericardial effusion, cardiac arrest, or tamponade.18 Patients with direct anatomic contact between the proximal LAA and PA may be at an increased risk of PA stenosis or injury.19 However, in our patient, cardiac-gated CT on postoperative day 4 showed normal device seating and no evidence of PA compression, cardiac effusion, or atypical positioning over the mitral valve. Instead, the patient’s net negative fluid balance of 3.87 L during hospitalization suggests diuresis as the more likely etiology of OH. The LAA plays a significant role in ANP regulation. It is conceivable that the pressure from the lobe of the Amplatzer Amulet could result in greater LAA stretch, tissue injury, and pressure to the ganglionated plexi, thus stimulating ANP secretion, natriuresis, and diuresis.9,20 Although ANP levels were not measured in our patient owing to limited commercial availability, his serum sodium decreased from 141 mmol/L before the procedure to 138 mmol/L within 24 hours after the operation, coinciding with a 3-L fluid output on postoperative day 1. Similar findings have been reported with epicardial exclusion devices, which show an approximately 3 mmol/L reduction in serum sodium at 24 hours, alongside moderate hypotension.8,10 In particular, Holmes et al8 observed that acute hyponatremia (defined as a >4 mmol/L reduction in serum sodium at 48 hours after the operation) was associated with hypotension in patients undergoing epicardial LAA closure, with larger left atrial diameter and lower body mass index identified as risk factors for acute hyponatremia. Although a 48-hour sodium level was not obtained in our patient, it is plausible that he developed acute, relative hyponatremia on postoperative day 2. Symptom improvement on postoperative day 4 coincided with normalization of serum sodium to 140 mmol/L after intravenous fluid administration, cessation of metoprolol, and initiation of fludrocortisone. These interventions may have counteracted the effects of ANP by removing inhibition of the renin-angiotensin-aldosterone system and promoting sodium reabsorption.21,22 Although the early reduction in serum sodium mirrors findings observed with epicardial devices, it may not fully account for the severity of OH observed in this case. Rather, ANP-mediated diuresis could have acted as the “tipping point” for an already vulnerable patient with several predisposing factors. Although he was taking finasteride, metoprolol succinate, donepezil, memantine, and trazodone before the procedure (all of which can cause bradycardia or hypotension as a potential side effect), the lack of preprocedural OH makes these medications an unlikely primary etiology.23, 24, 25, 26 He also had diabetic peripheral neuropathy, which is associated with diabetic autonomic neuropathy.27,28 Thus, in the context of advanced age, he could have had an unrecognized underlying autonomic disorder. The LAAO procedure may have then unmasked a previously subclinical orthostatic intolerance, through the combined stressors of general anesthesia (a known cause of transient OH after induction), device-related mechanostimulation, and ANP-mediated diuresis.29,30 Conclusion OH is a rare but clinically significant complication of LAAO procedures. Its etiology is likely complex and influenced by device size and placement, degree of ANP secretion, and preexisting susceptibility to OH. A treatment strategy involving intravenous volume expansion, supportive care over time, and adjustment of home medications may be successful. To the best of our knowledge, this is the first reported case of severe OH after LAAO successfully managed with pharmacologic therapy and conservative management. Funding Sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Disclosures The authors have no conflicts of interest to disclose. References